Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
Scientific Community
Become a Member | Sign in
Home>News>This Article

StemCells Inc. Advances Clinical Trial in AMD to Final Cohort

Published: Saturday, May 24, 2014
Last Updated: Saturday, May 24, 2014
Bookmark and Share
Phase I/II AMD trial on track to complete enrollment in June.

StemCells, Inc. has announced that it has transplanted the Company's proprietary HuCNS-SC® (purified human neural stem cells) into the first five patients in the final cohort of its 16-patient Phase I/II trial for geographic atrophy of age related macular degeneration (GA-AMD).

Each of the eight patients in this second cohort will receive a dose of 1 million stem cells into the most affected eye.

"We are very pleased with the rate of progress being made towards our goal of completing enrollment in this study by the end of this quarter," said Stephen Huhn, M.D., FACS, FAAP, Vice President, CNS Clinical Research at StemCells, Inc.

Huhn continued, "We look forward to releasing the first interim results from this study next month and are planning to initiate a controlled Phase II proof-of-concept study later this year."

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

StemCells, Inc. Appoints Dr. Alan Trounson
Company announces appointment of Dr. Trounson to its Board of Directors.
Thursday, July 10, 2014
StemCells, Inc. Announces Closure of Enrollment in Phase I/II Dry AMD Trial
Phase II clinical trial to begin this year.
Tuesday, June 24, 2014
StemCells, Inc. Strengthens Senior Executive Team
Company appoints Joel Naor, Naymisha Patel and Mohammad A. El-Kalay and promote Stephen Huhn to the position of vice president.
Thursday, June 19, 2014
StemCells, Inc. Appoints Greg Schiffman as Chief Financial Officer
Mr. Schiffman will join Company’s executive team, effective January 1, 2014.
Friday, November 15, 2013
StemCells Initiates Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration
Leading cause of blindness in elderly.
Thursday, June 28, 2012
StemCells Initiates Phase I/II Clinical Trial in Dry Age-Related Macular Degeneration
Leading cause of blindness in elderly.
Thursday, June 28, 2012
StemCells, Inc. Announces Publication of Preclinical Data Demonstrating Its Human Neural Stem Cells Preserve Vision
HuCNS-SC(R) cells (purified human neural stem cells) found to protect host photoreceptors and preserve vision in an animal model of retinal disease.
Monday, January 30, 2012
StemCells, Inc. Announces Closing of Public Offering of Common Stock and Warrants
The company announced that it has closed its previously announced underwritten offering of an aggregate of 8,000,000 units and 8,000,000 Series B Warrants, each to purchase one unit, at a public offering price of $1.25 per unit.
Friday, December 23, 2011
Stemcells, Inc. To Present At 2011 Stem Cell Meeting
StemCells, Inc. have announced that Martin McGlynn, President and CEO, will present a business update at the 2011 Forum.
Tuesday, November 29, 2011
World’s First Neural Stem Cell Transplant in Spinal Cord Injury Patient
The transplant surgery was performed by a team of surgeons led by Dr. Raphael Guzman and Dr. K. Min.
Monday, September 26, 2011
Stemcells, Inc. Awarded CIRM Planning Grant to Pursue Preclinical Development of HuCNS-SC Cells for Alzheimer’s Disease
CIRM has approved the Company’s application for a “Disease Team Therapy Development Planning Award.”
Friday, September 02, 2011
StemCells Regains Compliance for Continued NASDAQ Global Market Listing
Company has received notification from The NASDAQ stock market that the Company has regained compliance with the minimum bid price requirement.
Friday, July 22, 2011
Stemcells, Inc. Relocates Corporate Headquarters and U.S. Research Labs
Corporate headquarters and U.S.-based research and development operations relocate to 7707 Gateway Blvd, Newark, CA 94560, USA.
Wednesday, July 20, 2011
Stemcells to Present Clinical Evidence of Long-term Survival of HuCNS-SC® Cells Following Completion of Immunosuppression Regimen
The data will be reported at the International Society for Stem Cell Research (ISSCR) 9th Annual Meeting, June 15-18 in Toronto, Ontario.
Thursday, June 16, 2011
StemCells, Inc. Reports First Quarter Financial Results and Announces Reduction in Force
Company to reduce US-based workforce by 30 percent to reduce its cash burn rate and extends financial resources to focus on advancing the clinical development of HuCNS-SC® cells.
Friday, May 06, 2011
Scientific News
How a Genetic Locus Protects Adult Blood-Forming Stem Cells
Mammalian imprinted Gtl2 protects adult hematopoietic stem cells by restricting metabolic activity in the cells' mitochondria.
Fat Cells Originating from Bone Marrow Found in Humans
Cells could contribute to diabetes, heart disease.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
CRI Identifies Emergency Blood-formation Response
Researchers report that when tissue damage occurs, an emergency blood-formation system activates.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
Promise of Newborn Stem Cells to Revolutionize Clinical Practice
In this article Shweta Sharma, PhD, discusses the potential of an Umbilical Cord Blood bank as an untapped source of samples for research and clinical trials.
The Life Story of Stem Cells
A model analyses the development of stem cell numbers in the human body.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Advancing Genome Editing of Blood Stem Cells
Genome editing techniques for blood stem cells just got better, thanks to a team of researchers at USC and Sangamo BioSciences.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos